CODEN: WJAPAC Impact Factor: 3.87 ISSN: 3049-3013

World Journal of Advance Pharmaceutical Sciences

Volume 2, Issue 1. Page: 125-133 Review Article www.wjaps.com

A REVIEW OF THE INTEGRATION OF AI IN MODERN DRUG DISCOVERY AND DEVELOPMENT

Dr. T. Vinciya*[1] and P. Senthil Kumar[2]

[1]Department of Pharmacology, Faculty of Pharmacy, Dr. M.G.R Educational and Research Institute, Chennai-600077.
[2]Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Dr. M.G.R Educational and Research Institute, Chennai-600077.

How to cite this Article Dr. T. Vinciya and P. Senthil Kumar (2025). A REVIEW OF THE INTEGRATION OF AI IN MODERN DRUG DISCOVERY AND DEVELOPMENT. World Journal of Advance Pharmaceutical Sciences, 2(1), 125-133.

Article Info

Article Received: 17 April 2025,

Article Revised: 07 May 2025,

Article Accepted: 27 May 2025.

DOI: https://doi.org/10.5281/zenodo.15546013

***Corresponding author:**

***Dr. T. Vinciya**

Department of Pharmacology, Faculty of Pharmacy, Dr. M.G.R Educational and Research Institute, Chennai-600077.

ABSTRACT

Drug discovery and development is going through a revolution with artificial intelligence (AI) which gives faster and cheaper solutions than traditional methods. AI-driven active learning is becoming more and more common in drug development as it finds important information inside large chemical spaces even with very little labeled data. By screening compounds and improving lead molecules, AI can find potential drug candidates by reducing the time and resources needed to get from hit to lead. CADD has greatly impacted this field. Another advantage of using CADD with AI, ML, and DL to manage large biological data is the time and cost of drug development has decreased. Deep learning and AI are necessary to organize and evaluate the data generated by combinatorial chemistry. This helps de novo, virtual screening, and structure-based drug design. Because active learning can find useful information even with minimal labelled data it's a great approach for drug development. This approach addresses the challenges posed by data in the broad realm of chemistry. The article delves into the role of learning in drug development across stages such as predicting compound interactions, conducting screenings, designing and optimizing molecules, and forecasting properties. It also explores the obstacles and future potential of learning in drug development. Notably, structure-based drug design is gaining importance as a method to accelerate and streamline lead discovery compared to traditional methods. Moreover, artificial intelligence and deep learning technologies are employed to analyze and organize data sets in the drug discovery domain. Additionally, advanced machine learning tools driven by AI significantly influence the drug discovery process including areas of medicinal chemistry.

KEYWORDS: Active Learning, Computer-Aided Drug Design (CADD), Machine Learning (ML), Structure-Based Drug Design, Deep Learning.

1. INTRODUCTION

Artificial intelligence is a potent technology that may be used to speed up the process of finding new drugs, cut costs and time, and increases the rate of success of clinical trials. AI is capable of identifying possible therapeutic targets through the analysis of vast volumes of biological data, forecasting toxicity and efficacy, and maximizing drug development through the prediction of the best possible dose, formulation, and delivery system. Virtual screening, which predicts a compound's propensity for binding to a target protein, is another application of AI that enables researchers to swiftly find promising drug candidates from vast databases. To determine the patients most likely to gain advantages

from a certain medication, AI may also evaluate clinical trial data. This can increase the success rate of clinical studies while cutting costs and time.[1] Both medication research and artificial intelligence (AI) have extensive histories, and their paths have converged as a result of improvements in computing and experimental, technological capacities. John McCarthy popularized artificial intelligence (AI) in 1956, drawing inspiration from Hebrew folklore, Greek mythology, and alchemists such as Roger Bacon and Paracelsus. Russell, Whitehead, Hilbert, and others created mathematical logic in the 20th century, which is essential to artificial intelligence. The names Lovelace, Babbage, and Shannon, among others, Turing, as well as Minsky, McCarthy, Newell, and Simon now all acknowledge artificial intelligence. Clinical drug development and drug discovery/design/preclinical optimization are the two primary subsets of drug development. The first has a long and illustrious history and is still quite sophisticated. One of the biggest issues that has to be resolved is the confluence of AI and medication development.[2] Many computational techniques have been developed in recent decades to speed up and lower the cost of drug discovery while also enhancing the quality and success rate of the development process. Artificial Intelligence (AI) is being used more and more in drug development processes such as ADME-Tox prediction, chemical optimization, drug-like molecule synthesis, molecular target discovery, and clinical trials. Schneider and colleagues emphasized the advantages of artificial intelligence (AI) techniques in drug development because of their capacity to generate prediction models for big chemical datasets.[3] There are still issues, though, including the lack of reliable datasets, the need for de novo design to explore the chemical area, optimization with multiple goals, cycle time reduction, the need for mathematical researchers and medicinal chemists to collaborate, and the creation of opportunities for AI and computation cheminformatics techniques to work together.[4] Numerous pharmacological compounds have been developed due to the huge chemical space, which has over 1060 molecules. Artificial Intelligence (AI) is a multidisciplinary field within science and technology that is devoted to the development of intelligent entities, primarily computer programs.[5] Artificial Intelligence (AI) can help alleviate medication research's time-consuming and costly nature, which is hindered by a lack of modern technological tools.[6] AI can identify compounds that are hits and leads, validate therapeutic targets more quickly, and optimize drug structure design.[7]



Figure 1: Role of Artificial Intelligence in Drug Discovery Process.

The pharmaceutical industry is becoming more interested in artificial intelligence (AI) due to its potential to completely transform the process of finding new drugs. AI is used for a wide range of areas, including business, education, finance, and in social media, where the application improves decision-making, automate procedures, personalizes interactions and draws insightful conclusions from massive volumes of data.[8] Artificial intelligence (AI) methods that enable accurate and efficient analysis of vast volumes of data, such as machine learning and the processing of natural language can enhance the procedure. AI systems use machine learning algorithms and technologies to carry out tasks like problem-solving and logical reasoning either fully or partially on their own.[9] The capacity of AI to increase the effectiveness of drug research is demonstrated by the successful application of deep learning to predict drug toxicity and efficacy. To properly comprehend the benefits and constraints of AI in this field, further study is necessary as well as ethical considerations that must be

made. Notwithstanding these obstacles, AI is anticipated to have a major impact on the creation of novel drugs and treatments in the years to come.[10]

2. Role of AI and Active Learning

2.1 AI-Driven Active Learning in Drug Development

Active learning may effectively find useful data even with a small amount of labelled data, making it a promising strategy for drug development. The potential of AL in automated data curation has made it possible to train strong machine learning models with small datasets.[11] Molecular generation and optimization, virtual screening, compound-target interaction prediction, and molecular property prediction are some of the phases of drug development where active learning is being utilized more and more. The difficulties and opportunities to use active learning for drug development are also covered in the study.[12] With its capacity to sample informative data from noisy datasets, AL can result in high prediction accuracy with lesser training data.[13] Active machine learning effectively chooses the most instructive experiments to expedite and enhance drug discovery models. Even while active learning technology has been around for a while, its use in drug development has been sluggish. Driven by increased enthusiasm for artificial intelligence and advancements in lab automation, active machine learning is anticipated to become a significant technique for molecular optimizations.[14] Using active machine learning, data collection, and model training may be guided and optimized in drug development. Molecular discovery and drug discovery optimization have been demonstrated to be guided by active machine learning. To train models on tiny datasets, active machine learning may be employed for automatic data curation.[15] In modern times, active learning has increasingly emerged as a successful strategy used to counter problems such as growth of chemical spaces and sparse labelled data during drug discovery. There is extensive use of AL across several phases of drug development that includes virtual screening, the prediction of molecular properties, and prediction of the compound-target interaction.[16] The intricacy of biological systems makes machine-learning techniques essential for developing new drugs in the future. To address the dimensionality issue in drug research, machine vision algorithms for information extraction from imaging tests will be necessary. It will also be important to use active learning techniques to direct testing to solve the dimensionality issue in medication development.[17]

2.2 Benefits of AI in Drug Development

The discovery and optimization of novel drug candidates have been expedited by AI, revolutionizing the field of drug development. AI is capable of analyzing big datasets to pinpoint possible therapeutic targets and enhance lead compounds. AI has the potential to enhance patient selection and clinical trial design, which will increase success rates and advance customized medicine.[18] Large compound libraries can be quickly screened by AI an algorithm, which improves the identification of possible therapeutic candidates and forecasts their safety and efficacy profiles.[19] Artificial Intelligence has the potential to decrease the time and costs associated with moving drug candidates from "hit" to "lead" status. With applications in drug development, customized treatment, and health outcome improvement, artificial intelligence (AI) holds great promise for the biopharmaceutical sector. By utilizing data from target identification, biochemistry, and genetics, artificial intelligence has completely changed methods for diagnosing and treating diseases. Through the use of data from proteomics, genetics, and other life sciences, artificial intelligence (AI) can provide breakthrough insights into medicine and accelerate the process of drug discovery and development.[20] Better dose formulations, less toxicity, and increased target accuracy have all been made possible by the use of AI and ML within the drug development and discovery processes. Utilizing AI and ML in medicine formulation has improved resource efficiency and made it possible for pharmaceuticals to be 3D printed online. It will take cooperation between technology and pharmaceutical businesses to successfully integrate AI and ML into medication discovery and development.[21]

3. Computer-Aided Drug Design (CADD)

3.1 Impact of CADD

CADD employs two distinct methodologies, contingent upon the accessibility of either ligands or three-dimensional protein structures. They are known as structure-based drug design (SBDD) and ligand-based drug design (LBDD). The combination of the two methods has occasionally demonstrated good accuracy in locating the lead molecules. The potential for computer-aided drug design (CADD) to expedite and reduce the cost of the drug development process has generated a great deal of interest in this growing sector. Drug development process time and expense have decreased due to the integration of Artificial Intelligence (AI), Machine Learning (ML), and Deep Learning (DL) technologies with CADD to manage massive volumes of biological data.[22]

a. ARTIFICIAL INTELLIGENCE

AI-based non predetermined scoring functions are the subject of ongoing study and have been confirmed through their application in predicting ligand-binding affinity for several biological systems. How to build such models most effectively and whether they could benefit from new chemical representations are open concerns. The field of artificial intelligence (AI), and specifically its subclass of deep learning, presents prospects for the identification and creation of novel pharmaceuticals.[23] Recently, several machine learning techniques have (re)emerged; some of these could be seen as examples of domain-specific AI that has been effectively applied to drug design and discovery.AI techniques are used in small-molecule drug development nowadays, with a particular focus on the benefits and drawbacks of

cutting-edge algorithms.[24] Offers instructions for building an AI model in medicinal chemistry along with a breakdown of the variables influencing the model's performance. It discusses the successes and difficulties encountered by well-established AI- related methods for the discovery of small molecules. It makes an effort to anticipate future opportunities for AI-assisted drug discovery by integrating with other fields, such as chemistry and the various omics fields.[25]

MACHINE LEARNING-A subfield of artificial intelligence and computer science called "machine learning" aims to replicate human learning by steadily improving the accuracy of algorithms and data. This is a new area of data science that creates predictions or classifications using statistical techniques and trained algorithms, exposing important data mining insights.[26] Based on the techniques and methods of learning, machine learning can be divided into four groups: semi-supervised, reinforcement learning, supervised learning, and unsupervised learning. Significant tasks for AI systems in a large dataset include pattern recognition, regression, grouping, and classification.[27] With the use of machine learning approaches, pharmaceutical data can be used for more accurate decision-making in a variety of applications, such as QSAR analysis, hit discoveries, and de novo drug designs.[28]

DEEP LEARNING- Deep learning is a subfield of machine learning. It's an algorithm for abstracting data that uses various non-linear transformations or processing layers of intricate structures. Convolutional neural networks (CNN), recurrent neural networks (RNN), and artificial neural networks (ANN) are a few types of supervised deep learning techniques.[29] Artificial neural networks, or deep learning neural networks, mimic the functioning of the human brain by combining weights, biases, and data inputs. Together, these components enable reliable identification, categorization, and characterization of objects in the data. Deep learning approaches can be divided into two categories-supervised and unsupervised. Deep learning is the term for machine learning methods that use multiple layers to extract higher- level features from unprocessed input.[30] A sizable percentage of prospective medications are rejected by regulators. Failure can have several causes, including insufficient effectiveness (on-target effect), undesired interactions (off-target effects), or unanticipated dangerous outcomes. Deep learning has been used to forecast bimolecular targets, off-targets, and hazardous consequences of environmental chemicals in foods, home products, and pharmaceuticals.[31]

4. Applications of AI in Drug Development

4.1 Data Management with AI

Artificial Intelligence is a potential approach to deal with the changing healthcare scenario. Blockchain technology is essential for AI applications in healthcare because it can securely store encrypted records. This interface allows healthcare providers to access patient health records while AI employs recommended algorithms and decision-making capabilities, thus encouraging a more service-efficient, cost-effective, and democratized healthcare system. By incorporating cutting-edge technologies, massive data sets may now be handled much more effectively in real time, leading to quicker disease detection, diagnosis, and automated treatment choices. Advances in machine learning algorithms, more affordable hardware, easier access to data, and the arrival of 5G technology are driving the growing use of AI. Change occurs more quickly as a result of these elements working together to cause a shift. Some of the technologies used for data management in healthcare. Artificial intelligence systems excel at swiftly and reliably assessing patient data by spotting important patterns. AI improves diagnostic accuracy, which enables earlier and more precise diagnosis of medical diseases and, consequently, more focused and timely therapies. AI improves diagnostic accuracy, which enables earlier and more precise diagnosis of medical disorders. Significant issues with data security and privacy are brought up by integrating AI into data management. Adequate training initiatives and proficient change management tactics are crucial for guaranteeing user compliance and seamless integration.[32]

4.2 Applications in Drug Discovery

CADD is the process of developing new drugs by applying computer modelling methods. The process of bringing a novel medicine to market is very time-consuming, costly, and hazardous in terms of labour, money, and resources. It also takes ten to fifteen years to develop a drug to a respectable degree. Preclinical research, lead optimization, target validation, and target selection are among the stages of drug development that can be addressed by CADD. It is estimated that CADD might reduce the cost of drug development by as much as 50%. Homology modelling, molecular docking, virtual screening (VS) or virtual high-throughput screening (vHTS), quantitative structure-activity relationship (QSAR), and frequently three-dimensional (3D) pharmacophore mapping are the fundamental elements of CADD.[33] The study of computer science's artificial intelligence (AI) includes information gathering, rule development, and behavior imitation. The creation of intelligent computer systems that can function with little to no human involvement is the core idea underlying artificial intelligence (AI). These rule-based systems can handle complicated issues since they are built with a variety of deep learning and machine learning models. AI is incorporated with these models to learn, understand, and evaluate provided data. Artificial Intelligence (AI) is changing several industries at a rapid pace; one industry that is particularly being affected is the pharmaceutical industry. AI is being used more and more in the pharmaceutical sector to automate, optimize, and personalize many aspects of the business, especially in pharmacological research. Traditional drug development procedures are known for being time-consuming, expensive, and less efficient, frequently

taking around a decade and costing billions of dollars. These issues are addressed by the incorporation of artificial intelligence (AI) tools, which make it possible to identify compounds with the needed qualities among a large number of input medications. By increasing the efficiency and accuracy of forecasting drug behavior, interactions, and attributes, artificial intelligence (AI) improves the drug design process.[34]

DE NOVO DRUG DESIGN-De novo design creates novel lead structures tailored to a certain target site using docking programs. The procedures of designing drugs from scratch identifying the binding pocket on the intended receptor, using Ligplot to predict the target receptor's interaction locations using Ligplot to predict the target receptor's interaction locations. Structurally alteration of the fragments to create probable interactions with the residues in the location of the target receptor, combining all the pieces to create a single, whole molecule.[35]

a) VIRTUAL SCREENING-Virtual screening is the term for *in silico* techniques for selecting interesting compounds from chemical databases. It can be thought of as the computerized counterpart of experimental biological evaluation techniques like high- throughput screening (HTS).[29] Utilizing extensive and chemically diverse compound libraries for computational and biological screening is a widely used approach in medication development.[36] Structure-based virtual screening (SBVS) and ligand-based virtual screening (LBVS) are the two categories into which VS are separated.

STRUCTURE-BASED DRUG DESIGN

The accessibility of the three-dimensional structures of the therapeutic target protein and the characterization of the binding site cavity (BSC) are fundamental concepts of structure-based drug design.[37] A new era of SBDD in drug discovery and design has begun by disclosing many biological molecules' three-dimensional (3D) structures. SBDD has surfaced as a potential method in the pharmaceutical sector for producing and optimizing ligands. The fundamental steps in SBDD include target preparation, binding site identification, molecular docking, virtual screening, and molecular dynamics.[29]

STEPS INVOLVED IN STRUCTURE-BASED DRUG DESIGN

TARGET IDENTIFICATION- In SBDD, the most important stage is preparing the structure of the target macromolecule. Since X-ray and NMR structure elucidation techniques have advanced so quickly, it is now possible to retrieve the 3D structures of proteins stored in the Protein Data Bank (PDB).[38] If the three-dimensional structures of the target proteins are not available, computational techniques such as homology or comparative modeling.[39]

ACTIVE BINDING SITE IDENTIFICATION AND PREPARATION- The interaction of a protein with a ligand is required for drug activity, and this can only occur if high-affinity binding sites are identified. The identification of druggable cavities or pockets on a target protein is a critical step in the development of novel approaches in a structure-based drug discovery method. The term "binding sites" (BSs) refers to protein surface cavities that can vary significantly in size and shape.[40,41] The in-silico tools used to predict the binding sites of a target protein include POCKET, SURFNET, Q-SITE FINDER, DoGSite Scorer service, CASTp, N Site Match, metapocket, DEPTH, LISE, and MSpocket.[29] Once the binding site has been identified, instruments or servers like Epock.[42] To find the binding pocket's volume, utilize POVME and TRAnsient Pockets in Proteins (TRAPP), utilize to find the binding pocket volume.[29]

MOLECULAR DOCKING – The method for figuring out ligand molecules' conformation and orientation collectively referred to as "position" in the binding site of a macromolecular target is called molecular docking. Pose generation is done by search algorithms, which are then scored. A wide range of biological activities, including signal transduction, cell regulation, and other macromolecular assemblies, depend on molecular recognitions, including those between enzymes and substrates, drugs and proteins, drugs and nucleic acids, proteins and nucleic acids, and interactions between proteins. Two essential elements of a protein-ligand docking technique are sampling and scoring. Two aspects of sampling, related to generating potential ligand binding orientations/conformations close to a protein's binding site, are ligand sampling and protein flexibility. Using physical or empirical functions, scoring predicts binding tightness for specific ligand orientations/conformations.[43, 44, 45]

5. Challenges in AI-Driven Drug Development

5.1 Challenges in Chemical Data

Even though AI has great potential for drug discovery, some several obstacles and restrictions need to be taken into account. The availability of appropriate data is one of the main obstacles. A lot of data is usually needed for AI-based methods to train them. The accuracy and dependability of the results can frequently be impacted by the limited quantity, variable quality, or poor quality of the data that is available. Ethical issues may provide a hurdle because AI-based solutions may give rise to questions regarding prejudice and justice (see the following section). For instance, biased or unrepresentative training data may result in unfair or erroneous predictions from an ML algorithm. The challenges that artificial intelligence (AI) faces in the context of chemical medicine can be addressed in several ways. Data augmentation is a strategy that includes creating artificial data to enhance pre-existing datasets. This can improve the amount and variety of data available for ML algorithm training, enhancing the

precision and dependability of the outcomes. Using explainable AI (XAI) techniques, which seek to offer explicit and comprehensible justifications for the predictions generated by machine learning algorithms, is an additional strategy. This can lead to a deeper understanding of the underlying mechanisms and assumptions behind the forecasts and help allay worries about bias and fairness in AI-based initiatives. Modern AI- based techniques cannot take the place of conventional experimental procedures or the knowledge and experience of human researchers. Only data that is currently accessible can be used by AI to make predictions; human researchers must then verify and interpret the findings. But combining AI with conventional experimentation techniques can also improve the drug-finding process. Drug discovery can be sped up and the development of novel drugs can be optimized by fusing artificial intelligence's predictive power with the knowledge and experience of human researchers.[46]

6. AI Across Drug Development Stages

6.1 Predicting Compound Interactions

List of databases utilized to forecast the CPI. Three distinct categories-chemistry-centric, protein-centric, and integrated databases are used to arrange the databases. (A) The integration of data from chemical experiments is the primary goal of chemistry centric databases. They consist of the proteins that interact or target them with matching affinities, as well as SMILES, InChI keys, or other accession data. (b) Sequence information is generally available from protein databases. They seldom ever include information on chemical substances. (c) Other databases contain integrated data, such as associations with genes, diseases, or phenotypes, in addition to chemicals or proteins. Since the search space is a Cartesian product of two big dimensions the dimension for chemicals and the dimension for protein targets CPI data is by nature very high dimensional. Sadly, there are too many samples. As a result, for CPI prediction, a decision tree's generalization ability is fairly constrained. Suggested an AOPEDF, a network-based computational framework, to infer CPI prediction beyond the straightforward use of model predictors. Motivated by the research, they created a heterogeneous network by combining 15 networks—which covered phenotypic, genetic, chemical, and network profiles related to medications, proteins, and diseases—in a novel way. To infer novel drug-target interactions, the cascade deep forest classifier receives the network features as input. The commonly employed techniques for protein-ligand prediction. employing the based model, which rather than only generating a forecast answer, offers a trustworthy posterior mean of the outcomes.[47]

6.2 Molecule Design and Optimization

In molecular optimization, scientists typically gather their information from the aforementioned sources by specific optimization tasks. A matched molecular pair (MMP) is defined as two molecules with small differences between consecutive atoms but large differences between properties. There is a great deal of interest in drug discovery, specifically in the areas of pharmacokinetic properties, medicinal chemistry properties, physicochemical properties, and pharmacological properties. Researchers typically optimize some properties of molecules, such as drug-likeness (QED), octanol-water partition coefficient (log P), octanol-water distribution coefficient (log D), molecular bioactivity against drug targets (for example, DRD2, GSK3β, and JNK3), as well as selectivity. A collection of pharmacokinetic characteristics known as ADMET provides information on how a medicine interacts with the human body. QED is a type of medicinal chemistry feature that quantifies a molecule's propensity to be a good candidate for a medication. SA stands for, respectively, the simplicity of molecular synthesis. The solubility of a chemical is measured by log P and log D. The source molecule in an MMP is named the desired molecule, and the target molecule is named the molecule with poor properties. This information is based on a study. MMPs from ChEMBL and their ADMET characteristics. Since it is challenging to gather MMPs related to all optimized properties, researchers attempt to gather two sets of molecules with significantly different properties. These sets of molecules are referred to as matched molecular sets (MMS); the source molecular set is the set of molecules in an MMS that have poor properties, and the target molecular set is the set of molecules that have desired properties. A property predictor often evaluates the pharmacological qualities, while RDKit typically evaluates the other properties. Furthermore, ensuring the structural similarity of molecules before and after optimization-a task that is typically computed by RDK it is essential to molecular optimization.[48]

7. Future of AI in Drug Discovery

7.1 Obstacles and Opportunities

Drug discovery is about to undergo a revolution thanks to artificial intelligence (AI), which will increase the speed, accuracy, and efficiency of finding possible candidates for drugs.[49] AI has the potential to completely transform the drug development process by enabling quick screening of chemical libraries and making predictions about the safety and efficacy of therapeutic candidates. Nevertheless, there are obstacles to overcome before AI can be widely used in drug development. These include the requirement for varied and high-quality data, guaranteeing the understanding of AI designs, and handling moral issues like prejudice and data privacy.[50] AI is being used to discover novel therapeutic targets, create new compounds, and forecast the safety and effectiveness of prospective medications, among other stages of the drug research and development process. By testing millions of molecules in only a couple of hours, artificial intelligence (AI) may dramatically speed up the drug development process and identify promising potential therapies that would have

taken years to locate using traditional approaches being used in the pharmaceutical sector for purposes other than drug discovery, such process optimization, waste reduction, and quality control.[51] Although deep learning techniques have begun to address some of the major issues in drug discovery, there is still more space for advancement through the creation of more sophisticated methods. The development of multitask learning, explainable AI, and meta- learning will result in prediction models that are more reliable and easier to understand, particularly in situations with less data. Predicting response circumstances will receive more attention, and models for natural language processing will be employed extensively for both forward synthesis and retrosynthesis prediction.[52] Tasks that require a lot of manual effort can be automated by AI in the drug development process. To make sense of vast amounts of complicated biological and regulatory data, AI can interpret and integrate has the potential to improve knowledge discovery, particularly in the early stages of medication research.[53] Future pharmaceutical development and research are anticipated to be significantly impacted by AI technology as it develops.[51]

7.2 Influence on Medicinal Chemistry

Artificial intelligence (AI) is transforming medicinal chemistry and drug development by providing prospects for quicker and more economical lead identification when compared to conventional methodologies, structure-based drug design has become a vital tool for quicker and more affordable lead discovery. Deep learning and artificial intelligence are essential to the systematization and analysis of bigger data sets used in drug research. The process of finding new drugs, including medicinal chemistry, is greatly impacted by advanced machine- learning techniques powered by artificial intelligence.[54] AI is now widely used in pharmaceutical research and industry, making it possible to efficiently identify novel chemical entities with desired features systems is capable of analyzing large, complicated information to find possible therapeutic compounds and forecast the toxicity or efficacy of such chemicals. AI's ability to examine large chemical landscapes and identify meaningful patterns has demonstrated encouraging results in the creation of novel chemical scaffolds with medicinal promise.[55] Medical chemistry and drug development greatly benefit from AI and ML, especially when using recurrent networks, neural networks, and different kinds of algorithms. The pharmaceutical business has a wide range of uses for AI and ML, including medication development, repurposing, discovery, and clinical trials. AI and ML are utilized for de-novo synthesis, which creates new therapeutic compounds, and property prediction, such as ADMET, which can increase the efficacy, precision, and cost- effectiveness of drug research.[56] Development and discovery patterns for new drugs have an impact on medicinal chemistry tomorrow. In the search for therapeutic efficacy, dealing with 3D structure in data environments, making sure absorption occurs; guiding distribution, managing metabolism, maximizing excretion, and preventing toxicity are some of the topics covered. Medicinal chemistry will become increasingly important in the drug development process as combinations of chemicals and high-throughput testing are employed to analyze structure-activity connections. A future state of virtual techniques will be theoretical and experimental databases with verified clinical predictions. In addition, current developments in analytical and process chemistry are examined, including X-ray diffraction. Intellectual property connected to pharmaceuticals, education for aspiring medicinal chemists, and the conflict between molecular variety and knowledge in drug development are all covered in this article.[57] However, it is anticipated that the use of AI in drug development and research will have a big influence on medicinal chemistry in the future.[58]

8. CONCLUSION

AI is the game-changer for drug discovery and development, with radical acceleration of procedures, cost reduction, and improvement in precision for forecasting safety and efficacy. CADD, DL, and ML techniques have now enabled scientists to explore large chemical spaces, which will allow better drugs to be discovered and their clinical trials to move expediently forward. Even though data quality and ethical constraints remain, the inclusion of AI into pharmaceutical research has huge promise in promoting innovation in personal medicine and therapeutic improvement. Advances in AI are said to potentially affect the field of drug discovery significantly in the future and must be taken into consideration to deal with complex biological systems and improve patients' outcomes.

REFERENCES

1. Mhatre, G.S. (2023). Artificial Intelligence in Drugs Discovery and Development. *INTERANTIONAL JOURNAL OF SCIENTIFIC RESEARCH IN ENGINEERING AND MANAGEMENT*.
2. Liebman, M.N. (2022). The Role of Artificial Intelligence in Drug Discovery and Development. *Chemistry International, 44:* 16 - 19.
3. Lin, X., Li, X., & Lin, X. (2020). A review on applications of computational methods in drug screening and design. *Molecules*, *25*(6): 1375.
4. Hessler G, Baringhaus K-H (2018) Artifcial intelligence in drug design. Molecules, 23(10): 2520. https://doi.org/10.3390/molec ules23102520.
5. Nitesh kumar Pandey, Sanyam Kumat PS Shalani Pathak,. A Review Paper on Artificial Intelligence [Internet]. Vol. 44, Tuijin Jishu/Journal of Propulsion Technology. Science Research Society; 2023; 163–6. Available from: http://dx.doi.org/10.52783/tjjpt.v44.i1.2230
6. Rana A, Singhal N, Badotra S. A review paper on artificial intelligence. ACADEMICIA: An International Multidisciplinary Research Journal,

2021; 11(10): 249-56.
7. Sellwood, M. A., Ahmed, M., Segler, M. H., & Brown, N. (2018). Artificial intelligence in drug discovery. *Future medicinal chemistry*, *10*(17): 2025-2028.
8. Saxena P, Saxena V, Pandey A, Flato U, Shukla K. Multiple aspects of artificial intelligence. Book Saga Publications, 2023 Jul 2.
9. Morandín-Ahuerma F. Recommendation of the OECD council on artificial intelligence: inequality and inclusion1.
10. Blanco-Gonzalez, A., Cabezon, A., Seco-Gonzalez, A., Conde-Torres, D., Antelo-Riveiro, P., Pineiro, A., & Garcia-Fandino, R. (2023). The role of AI in drug discovery: challenges, opportunities, and strategies. *Pharmaceuticals*, *16*(6): 891.
11. Ding X, Cui R, Yu J, Liu T, Zhu T, Wang D, Chang J, Fan Z, Liu X, Chen K, Jiang H. Active learning for drug design: a case study on the plasma exposure of orally administered drugs. Journal of Medicinal Chemistry, 2021 Nov 15; 64(22): 16838-53.
12. Wang, L., Zhou, Z., Yang, X., Shi, S., Zeng, X., & Cao, D. (2024). The present state and challenges of active learning in drug discovery. *Drug discovery today*, 103985.
13. Pasrija P, Jha P, Upadhyaya P, Khan MS, Chopra M. Machine learning and artificial intelligence: a paradigm shift in big data-driven drug design and discovery. Current Topics in Medicinal Chemistry, 2022 Aug 1; 22(20): 1692-727.
14. Reker, D. (2019). Practical considerations for active machine learning in drug discovery. *Drug discovery today. Technologies*, *32-33*, 73-79.
15. Reker, D. (2020). Chapter 14. Active Learning for Drug Discovery and Automated Data Curation.
16. Gallego V, Naveiro R, Roca C, Rios Insua D, Campillo NE. AI in drug development: a multidisciplinary perspective. Molecular Diversity, 2021 Aug; 25: 1461-79.
17. Murphy, R.F. (2011). An active role for machine learning in drug development. *Nature chemical biology*, *7 6:* 327-30.
18. Unogwu, O.J., Ike, M., & Joktan, O.O. (2023). Employing Artificial Intelligence Methods in Drug Development: A New Era in Medicine. *Mesopotamian Journal of Artificial Intelligence in Healthcare*.
19. Tiwari PC, Pal R, Chaudhary MJ, Nath R. Artificial intelligence revolutionizing drug development: Exploring opportunities and challenges. Drug Development Research, 2023 Dec; 84(8): 1652-63.
20. Mishra, D.K., & Awasthi, H. (2021). Artificial Intelligence: A New Era in Drug Discovery. *Asian Journal of Pharmaceutical Research and Development*.
21. Parvathaneni, M., Awol, A.K., Kumari, M., Lan, K., & Lingam, M. (2023). Application of Artificial Intelligence and Machine Learning in Drug Discovery and Development. Journal of Drug Delivery and Therapeutics.
22. Batool, M., Ahmad, B., Choi, S., 2019. A structure-based drug discovery paradigm. Int. J. Mol. Sci., 20(11): 2783. https://doi.org/10.3390/ijms20112783.
23. Hunde BR, Woldeyohannes AD. Future prospects of computer-aided design (CAD)–A review from the perspective of artificial intelligence (AI), extended reality, and 3D printing. Results in Engineering, 2022 Jun 1; 14: 100478.
24. Niazi SK, Mariam Z. Computer-aided drug design and drug discovery: a prospective analysis. Pharmaceuticals, 2023 Dec 22; 17(1): 22.
25. Xin Yang, Yifei Wang, Ryan Byrne, Gisbert Schneider, and Shengyong Yang, 2019. concepts of Artificial Intelligence for Computer-Assisted Drug Discovery. Chem. Rev., 2019; 119: 10520−10594.
26. Chandgude V, Kawade B. Role of Artificial Intelligence and Machine Learning in Decision Making for Business Growth. International Journal of Advanced Research in Science, Communication and Technology, 2023; 54-8.
27. Carracedo-Reboredo, P., Linares-Blanco, ˜ J., Rodríguez-Fern´ andez, N., Cedron, ´ F., Novoa, F.J., Carballal, A., et al., 2021. review on machine learning approaches and trends in drug discovery. Comput. Struct. Biotechnol. J., 19: 4538–4558. https://doi. org/10.1016/j.csbj.2021.08.011.
28. Dara, S., Dhamercherla, S., Jadav, S.S., Babu, C.H., Ahsan, M.J., 2021. Machine Learning in Drug Discovery: a Review. Artif Intell Rev., 1–53. https://doi.org/10.1007/s10462- 021-10058-4.
29. Divya Vemula, Perka Jayasurya, Varthiya Sushmitha, Yethirajula Naveen Kumar, Vasundhra Bhandari, 2023. CADD, AI and ML in drug discovery: A comprehensive review. European Journal of Pharmaceutical Sciences, 2023; 181: 106324. https://doi.org/10.1016/j.ejps.2022.106324
30. Schmidhuber, J., 2015. Deep learning in neural networks: an overview. Neural Netw, 61: 85–117. https://doi.org/10.1016/j.neunet.2014.09.003.
31. Dahl, G.E., Jaitly, N. and Salakhutdinov, R, Multi-task neural networks for QSAR predictions, arXiv preprint arXiv, 2014; 1406–1231. 10.3389/fncom.2016.00094.
32. Sumanth Tatineni, 2022. INTEGRATING AI, BLOCKCHAIN AND CLOUD TECHNOLOGIES FOR DATA MANAGEMENT IN HEALTHCARE. Journal of Computer Engineering and Technology (JCET) 2022; 5(01).
33. Ramen Kalita, Amir Ali, Madhusmita Kumari, Kunal Bhattacharya, Satyendra Deka and Satyasish Sandilya., 2022. Application of Computer Aided Drug Design in Drug Discovery. Recent Advances In Pharmaceutical Sciences (pp.43-53).
34. Simrandeep Singh, Navjot Kaur, Anita Gehlot., 2024. Application of artificial intelligence in drug design: A review. computers in biology and medicine, 2024; 179: 108810.
35. Injamul Hoque, Arkendu Chatterjee, Somenath Bhattacharya, Raj Biswas., 2017. An Approach of Computer-Aided Drug Design (CADD) Tools for In

Silico Pharmaceutical Drug Design and Development. International Journal of Advanced Research in Biological Sciences. http://dx.doi.org/10.22192/ijarbs.2017.04.02.009.

36. Kodadek, T., 2011. The rise, fall and reinvention of combinatorial chemistry. Chem. Commun, 47: 9757–9763. https://doi.org/10.1039/c1cc12102b.
37. Kawato, T., Mizohata, E., Shimizu, Y., Meshizuka, T., Yamamoto, T., Takasu, N., et al., 2015. Structure-based design of a streptavidin mutant specific for an artificial biotin analogue. J. Biochem, 157(6): 467–475. https://doi.org/10.1093/jb/mvv004.
38. Vyas, V.K., Ukawala, R.D., Ghate, M., Chintha, C, 2012. Homology modelling a fast tool for drug discovery: current perspectives. Indian J. Pharm. Sci., 74(1): 1. https://doi. org/10.4103/0250-474X.102537.
39. Lemer, C.M.R., Rooman, M.J., Wodak, S.J., 1995. Protein structure prediction by threading methods: evaluation of current techniques. Proteins: Struct. Funct. Genet, 23(3): 337–355. https://doi.org/10.1002/prot.340230308.
40. Liang, J, Woodward, C, Edelsbrunner, H, 1998. Anatomy of protein pockets and cavities: measurement of binding site geometry and implications for ligand design. Protein Sci., 7(9): 1884–1897. https://doi.org/10.1002/prot.24065.
41. An, J, Totrov, M, Abagyan, R, 2005. Pocketome via comprehensive identification and classification of ligand binding envelopes. Mol. Cell Proteomics, 4(6): 752–761. https://doi.org/10.1074/mcp.M400159-MCP200
42. Laurent, B., Chavent, M., Cragnolini, T., Dahl, A.C., Pasquali, S., Derreumaux, P., et al., 2015. Epock: rapid analysis of protein pocket dynamics. Bioinformatics, 31(9): 1478–1480. https://doi.org/10.1093/bioinformatics/btu822.
43. Huang, S.Y., Zou, X., 2010. Advances and challenges in protein-ligand docking. Int. J. Mol. Sci., 11(8): 3016–3034. https://doi.org/10.3390/ijms11083016.
44. Jiang, F., Kim, S.H., 1991. Soft docking": matching of molecular surface cubes. J. Mol. Biol., 219(1): 79–102. https://doi.org/10.1016/0022-2836(91)90859-5.
45. Ferrari, A.M., Wei, B.Q., Costantino, L., Shoichet, B.K., 2004. Soft docking and multiple receptor conformations in virtual screening. J. Med. Chem., 47(21): 5076–5084. https://doi.org/10.1021/jm049756.
46. Alexandre Blanco-Gonzalez, Alfonso Cabezon, Alejandro Seco-Gonzalez, Daniel Conde- Torres, Paula Antelo-Riveiro, Angel Pineiro and Rebeca Garcia-Fandino., 2023. The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies. *Pharmaceuticals*, 2023; *16*(6): 891; https://doi.org/10.3390/ph16060891
47. Sangsoo Lim, Yijingxiu Lu, Chang Yun Cho, Inyoung Sung Jungwoo Kim, Youngkuk Kim et al., 2021. A review on compound-protein interaction prediction methods: Data, format, representation and model. computational and structural biotechnology journal, 2021; 19: 1541-1556. https://doi.org/10.1016/j.csbj.2021.
48. uhang Xia, Yongkang Wang, Zhiwei Wang, Wen Zhang., 2023. A comprehensive review of molecular optimization inartificial intelligence-based drug discovery. quantitative biology. https://doi.org/10.1002/qub2.30
49. Blanco-González, A., Cabezon, A., Seco-Gonzalez, A., Conde-Torres, D., Antelo-Riveiro, P., Piñeiro, Á., & García-Fandiño, R. (2022). The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies. *Pharmaceuticals, 16*.
50. Tiwari, P.C., Pal, R., Chaudhary, M.J., & Nath, R. (2023). Artificial intelligence revolutionizing drug development: Exploring opportunities and challenges. *Drug Development Research, 84:* 1652-1663.
51. Shiammala, P.N., Bose Duraimutharasan, N.K., Vaseeharan, B., Alothaim, A.S., Al-Malki, E.S., Snekaa, B., Safi, S.Z., Kumar Singh, S., Velmurugan, D., & Selvaraj, C. (2023). Exploring the Artificial Intelligence and Machine Learning Models in the Context of Drug Design Difficulties and Future Potential for the Pharmaceutical Sectors. *Methods*.
52. Jiménez-Luna, J., Grisoni, F., Weskamp, N., & Schneider, G. (2021). Artificial intelligence in drug discovery: recent advances and future perspectives. *Expert Opinion on Drug Discovery, 16:* 949 - 959.
53. Begoli, E., & Kusnezov, D. (2019). Artificial intelligence's essential role in the process of drug discovery. *Future Drug Discovery*.
54. Batool, M., Ahmad, B., & Choi, S. (2019). A Structure-Based Drug Discovery Paradigm. *International Journal of Molecular Sciences, 20*.
55. Han, R., Yoon, H., Kim, G., Lee, H., & Lee, Y. (2023). Revolutionizing Medicinal Chemistry: The Application of Artificial Intelligence (AI) in Early Drug Discovery. *Pharmaceuticals, 16*.
56. Quazi, S., & Jangi, R. (2021). Artificial Intelligence and Machine Learning in Medicinal Chemistry and Validation of Emerging Drug Targets.
57. Erhardt, P.W. (2002). Medicinal chemistry in the new millennium. A glance into the future. *Pure and Applied Chemistry, 74:* 703 - 785.
58. Mitchell, J.B. (2018). Artificial intelligence in pharmaceutical research and development. *Future medicinal chemistry, 10 13:* 1529-1531.